ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs.

The company currently has two novel drugs in the development pipeline. IC 100, an “ASC inflammasome inhibitor” treats inflammatory diseases. VAR200 is a “Cholesterol Efflux Mediator” targeting kidney disease.